Innovative BioPharma Company Inks Exclusive Agreement in South America

Innovative BioPharma Company Inks Exclusive Agreement in South America

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, April 13, 2022

With a pipeline of patent-pending drug candidates in various stages of clinical development and commercialization, this company has several cannabinoid-based drug candidates provide solutions for unmet medical needs to help treat dermatology, chronic pain, and various neurological disorders. 

Biopharma company Avicanna Inc. (TSX: AVCN) announced an exclusive license and supply agreement with an established South American pharmaceutical company to commercialize up to four of the firm's proprietary cannabinoid-based pharmaceutical preparations. 

Avicanna focused on the development and commercialization of plant-derived medical and pharmaceutical cannabinoid-based products. Per the company’s press release, its first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Shares of the firm closed Tuesday trade at $0.285.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top